Demonstrating that modulation of specific heterocomplex mediated signaling following co-treatment with hallucinogenic drugs and mGluR2/3 antagonists may work as a molecular switch between psychosis and AD activity [64], may fill the gap in knowledge about complex processes in the brain and open new avenues towards developing more effective new-age therapies for depression. Here, GRM2 is linked to depressive disorder.